Want to see JP:4593 full AI Analyst Report?
4593 Stock Chart & Stats
¥370.00
¥3.00(1.60%)
At close: 4:00 PM EST
¥370.00
¥3.00(1.60%)
Day’s Range― - ―
52-Week Range¥208.00 - ¥514.00
Previous CloseN/A
Volume811.70K
Average Volume (3M)1.40M
Market Cap
¥37.95B
Enterprise Value¥27.68B
Total Cash (Recent Filing)¥9.07B
Total Debt (Recent Filing)¥2.57B
Price to Earnings (P/E)56.7
Beta1.12
Next Earnings
Nov 12, 2026EPS Estimate
-12.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.96
Shares Outstanding135,545,600
10 Day Avg. Volume1,382,230
30 Day Avg. Volume1,404,100
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)6.03
Price to Sales (P/S)283.63
P/FCF Ratio-8.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-35.05
Revenue Forecast (FY)¥595.02M
Bulls Say, Bears Say
Bulls Say
Regenerative Medicine PlatformHealios is focused on regenerative medicine, somatic stem cells, and iPSC-derived cells across multiple therapeutic areas. This platform orientation can support several clinical and commercial opportunities over time, while manufacturing capabilities may strengthen its ability to advance cell-based therapies.
Improved Balance Sheet LeverageDebt-to-equity has improved substantially from prior years, reducing balance-sheet pressure and providing greater flexibility while clinical programs advance. Stronger equity and manageable leverage may help Healios sustain development activity, although continued losses could weaken this position.
Milestone-based Monetization ModelHealios’s collaboration and licensing model can monetize pipeline progress through upfront payments, development or regulatory milestones, and potential royalties. This structure provides multiple routes to future revenue and allows strategic partners to support development and commercialization.
Bears Say
Declining RevenueThe decline and volatility in revenue indicate that Healios has not yet established a stable commercial earnings base. Unpredictable top-line performance can make it harder to fund research, negotiate partnerships from strength, and demonstrate durable operating progress over the next several quarters.
Deep Operating LossesLarge operating losses and negative gross margin show that current revenue does not cover the cost base, leaving core operations economically unproven. Unless development and manufacturing economics improve, sustained losses may continue consuming capital and limit the company’s ability to scale independently.
Severe Cash BurnMaterially negative operating and free cash flow demonstrate that Healios is consuming cash rather than funding operations internally. Persistent burn increases dependence on financing, partnerships, or other non-operating sources and could pressure the improved balance sheet if losses continue.
Healios KK News
4593 FAQ
What was Healios KK’s price range in the past 12 months?
Healios KK lowest stock price was ¥208.00 and its highest was ¥514.00 in the past 12 months.
What is Healios KK’s market cap?
Healios KK’s market cap is ¥37.95B.
When is Healios KK’s upcoming earnings report date?
Healios KK’s upcoming earnings report date is Nov 12, 2026 which is in 19 days.
How were Healios KK’s earnings last quarter?
Healios KK released its earnings results on Aug 12, 2026. The company reported ¥10.13 earnings per share for the quarter, beating the consensus estimate of -¥2.429 by ¥12.559.
Is Healios KK overvalued?
According to Wall Street analysts Healios KK’s price is currently Overvalued.
Does Healios KK pay dividends?
Healios KK does not currently pay dividends.
What is Healios KK’s EPS estimate?
Healios KK’s EPS estimate is -12.47.
How many shares outstanding does Healios KK have?
Healios KK has 135,545,600 shares outstanding.
What happened to Healios KK’s price movement after its last earnings report?
Healios KK reported an EPS of ¥10.13 in its last earnings report, beating expectations of -¥2.429. Following the earnings report the stock price went down -1.55%.
Which hedge fund is a major shareholder of Healios KK?
Currently, no hedge funds are holding shares in JP:4593
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Healios KK
Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key markets including Japan, Europe, and the United States. Its robust pipeline features several cellular and tissue-based products, such as HLCR011 and HLCR012, which are induced pluripotent stem cell (iPSC)-derived regenerative medicines aimed at treating age-related macular degeneration. Another iPSC-based therapy, HLCL041, is being developed for metabolic liver disease. Furthermore, Healios is progressing HLCM051, a regenerative treatment designed for ischemic stroke and acute respiratory distress syndrome, alongside HLCN061 for solid tumor indications. The company also maintains a joint research partnership with Hyogo Medical University, focusing on eNK cell-based cancer immunotherapies to combat mesothelioma. Healios K.K. adopted its current name in September 2013, having previously operated under the name Retina Institute Japan, K.K.
Technical Analysis
SanBio Co
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―